All News

heart-attack.jpg

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

d Jack Cush, MD

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Read Article
OP_0.jpg

High Dose Statins Increase Odds of Osteoporosis

d Jack Cush, MD

It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis. A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent.

Read Article
obesity.back_.jpg

Comorbidity Worsens Axial Spondyloarthritis

d Jack Cush, MD

Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.

Read Article
infx.pneumonia.jpg

Myositis Patients at High Risk of Opportunistic Infections

d RheumNow

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Read Article
knee.surgery.jpg (keep)

One-Third of Psoriatic Arthritis Patients Will Need Joint Surgery

d Jack Cush, MD

Dannish study has shown that one-third of psoriatic arthritis (PsA) will have joint surgery that that PsA patients have twice the rate of joint surgery when compared with the general population.

Read Article
RA.vascular.cholesterol.plaque.jpg

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

d Jack Cush, MD

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Read Article
Survey for RHEUMATOLOGISTS - When choosing drug therapy for GCA, what mechanism are you targeting? IL-1, IL-6, TNF, or inflammation in general? Please vote at RheumNow >> https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

LIVE VOTE Survey: When treating a patient for GCA, when might you add a steroid-sparing agent?? If youre a RHEUMATOLOGIST - please vote in our RheumNow quick 4Q survey https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

The risks of pulmonary embolism after 6 types of surgery assessed using 60703 patients in a French national database. PE risk elevated for 12 weeks, highest in 6wks Pos-Op.

Dr. John Cush RheumNow ( View Tweet)

UK population study of 6591incident RA patients shows comorbidity increased all-cause mortality (aHR 1.26; 1-1.6). Joint destruction had no effect, but COPD was associated with significantly more mortality (COPD HR 2.84; 1.13-7.12). https://t.co/6ULPvq34qh

Links:

Dr. John Cush RheumNow ( View Tweet)

RHEUMATOLOGIST SURVEY - In what percentage of your GCA patients do you use a steroid-sparing agent? Few, Some, Many? RHEUMNOW Live Vote: Rheums Click here>> https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

LIVE VOTE RheumNow survey for Rheumatologists – When do you add a steroid sparing agent? https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

Evaluation of ANA testing in sytemic autoimmune dz (AID) finds low titers have low PPV. Highest PPV was for centromere pattern in PSS, w/ a PPV of 29% (1:160), 42% (1:32), 77% (1:640) & 82% (1:1280). Speckled PPV was low unti 1:1280 (PPV 71% for AID) https://t.co/JbDDXAOxOu

Links:

Dr. John Cush RheumNow ( View Tweet)

REcent trial results from the Dermatology Meeting EADV in Madrid —shows rituximab superior to mycophenolate in Pemphigus Vulgaris; RTX 40% vs MMF 9.5% attained complete remission of pemphigus vulgaris, without steroids for > 16 weeks https://t.co/PU9CbQSHJV

Links:

Dr. John Cush RheumNow ( View Tweet)

Single center study of anti-PhosphoLipd Abs in 149 Bx proven lupus nephritis pts 36% had APL Abs (18.8% IgG, 18.1% IgM, 10.7% B2GlyP, 8.1% LAC). F/U of 156 mos - APL+ had lower 10 yr survival (91 vs 99%). lower GFR, more thrombotic events & miscarriage https://t.co/U5ra02wMmX

Links:

Dr. John Cush RheumNow ( View Tweet)

SURVEY: When choosing drug therapy for GCA, what mechanism are you targeting? IL-1, IL-6, TNF, inflammation? Survey for RHEUMATOLOGISTS - please vote here>> https://t.co/qhpOxYz3Qt

Links:

Dr. John Cush RheumNow ( View Tweet)

Statin induced myopathy is occurs in less than 1%; rhabdomyolysis and necrotizing myositis are very rare. HMGCR Abs against (HMG-CoA) reductase are seen 2- 3 of every 100,000 patients treated with statins. https://t.co/44DGaHEGjo

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Survey for Rheumatologists – In Giant Cell Arteritis - When do you add a steroid sparing agent? https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

RISE registry: among 7,274 RA pts w/ serial data [RAPID3 (78.9%) & CDAI (34.2%)]. Amongst those w/ moderate/high disease activity, frequency of DMARD change was low (36%-55%). Less likely to change was elderly, Combo DMARDs or biologics. https://t.co/IppHCxJWk1

Links:

Dr. John Cush RheumNow ( View Tweet)

Followup of 783 tofacitinib‐treated psoriatic arthritis patients finds increases in LDL and HDL 9% to 14% after 3 and 6 months of therapy with a low risk of HTN or MACE events https://t.co/fh6UbmF3lr

Links:

Dr. John Cush RheumNow ( View Tweet)

×